Patient Gateway

RSS Feed

MAML-residual transformer for few-shot prediction of targeted therapy response in NSCLC

Evolving non-invasive biomarkers in NSCLC immunotherapy: integrating liquid biopsy and multi-omics profiling for precision oncology

YH42946, a novel and selective tyrosine kinase inhibitor, demonstrates potent antitumor activity against EGFR exon 20 insertion mutations and HER2 alterations in NSCLC

FDA approves GSK’s Jideytro for previously treated ROS1-positive NSCLC, the company’s first lung cancer clearance

Oliver Illini: Trastuzumab Deruxtecan Activity in HER2-Mutant NSCLC

Real-World T-DXd Outcomes in HER2-Mutant NSCLC – IASLC

HER2‐targeting zongertinib shows early activity in untreated advanced HER2‐mutant NSCLC

Sequential EGFR T790M, MET c.3010C>G-Associated Exon 14 Alteration, and RET-CCDC6 Fusion in EGFR-Mutant NSCLC: A Case Report

Miguel Gonzalez Velez: New Approval Expands Treatment Options for ROS1-Positive NSCLC